

**REMARKS**

Applicants have amended the specification to reference the prior filed applications from which the instant application claims benefit. Applicants respectfully contend that the requirements for submitting such an amendment under 37 C.F.R. §1.78(a)(2)(ii) and (a)(3) should be waived because the U.S. PTO has recognized the claim for benefit on both the Filing Receipt and on the cover page of the related U.S. Patent Application Publication (copies of which are attached). Applicants note that the Notice on Claiming the Benefit of Prior-Filed Applications from Deputy Commissioner Stephan Kunin dated February 24, 2003 specifically states that the requirements under 37 C.F.R. §1.78(a)(3)(ii) and (iii) will be waived if the “information concerning the claim was recognized by the Office as shown by its inclusion on the filing receipt.”

Claims 1-53 are pending in the instant application. The Examiner has stated that restriction to one of the following inventions is required under 35 U.S.C. 121:

- I. The compounds and composition according to Claim 1.
- II. The compounds and composition according to Claim 10.
- III. The method of treating according to Claim 29-53.

The Examiner has alleged that the inventions of Group I-III are separate and patentably distinct because there is no patentable co-action among them and a reference anticipating one member will not render another obvious. The Examiner has further alleged that a search of the three groups designated above would impose an undue burden upon the examiner, and restriction for examination purposes as indicated is proper. The Examiner advised Applicants that the reply to this requirement must include an election of a specifically disclosed species of the invention to be examined, even though the requirement is traversed, in order for the reply to be complete.

Applicants respectfully traverse the restriction. Applicants maintain that a search of the prior art which focuses on polymorphous salt forms of 4-[2-(5-cyano-thiazol-2-ylamino)-pyridin-4-ylmethyl]-piperazine-1-carboxylic acid methylamide would be comprehensive with respect to the instant invention yet would not require a serious burden on the Examiner. Applicants also respectfully request clarification as to which Group would cover independent claims 12, 14 and 19 (and their dependent claims). Applicants note that Section 803 of the MPEP provides:

There are two criteria for a proper requirement for restriction between patentably distinct inventions:

- (1) The inventions must be independent or distinct as claimed; and
- (2) There must be a serious burden on the examiner if restriction is not required.

Additionally, MPEP 803 indicates that :

If the search and examination of an entire application can be made without serious burden, the examiner must examine it on the merits, even though it includes claims to independent or distinct inventions.

Because there would be no serious burden on the Examiner in searching such closely related groups, Applicants respectfully contend that any restriction requirement would be improper. Additionally, Applicants respectfully note that research in the area of small molecule inhibitors of tyrosine kinase has taken place only in the last 20 years prior to the earliest priority date accorded the instant application. Applicants also note that the connection between tyrosine kinases, in particular KDR and macular degeneration, diabetic retinopathy and retinal ischemia has taken place only in the last 15 years. Applicants therefore respectfully contend that a search of the scientific and patent art in the twenty years prior to July 24, 2002 (the effective filing date of the instant application), for any disclosure of the use of the instant compound in the treatment of angiogenic associated diseases should be comprehensive with respect to the invention as originally claimed, yet clearly would not be an undue burden on the Examiner in light of the extensive electronic searching tools now available to the Examiner.

Applicants expressly note that Applicants are not arguing that the group elected by Applicants is not patentably distinct, but rather, contend that the Examiner should examine all of the groups of the instant invention since there would be no serious burden on the Examiner. For the reasons noted above, Applicants respectfully contend that the restriction requirement is improper and request that restriction be withdrawn.


However, to facilitate the Examiner's search under 37 C.F.R. 1.21 and to expedite prosecution of this application, Applicants elect Group I, which is directed to a polymorphous

form of a hydrochloride salt of 4-[2-(5-cyano-thiazol-2-ylamino)-pyridin-4-ylmethyl]-piperazine-1-carboxylic acid methylamide.

Applicants respectfully contend that Claims 1-53 as filed are allowable and an early Notice of Allowance is earnestly solicited. If a telephonic communication with Applicant's representative will aid in the advancement of the prosecution of this application, please telephone the representative indicated below.

Respectfully submitted,

By:



Diane Brown

Registration No. 42,068

Attorney for Applicants

MERCK & CO., INC.  
P.O. Box 2000 - RY 60-30  
Rahway, New Jersey 07065-0907  
Telephone No. (732) 594-1249

Date: February 16, 2006



US 20040023981A1

(19) United States

(12) Patent Application Publication (10) Pub. No.: US 2004/0023981 A1

Ren et al.

(43) Pub. Date: Feb. 5, 2004

(54) SALT FORMS WITH TYROSINE KINASE ACTIVITY

Publication Classification

(76) Inventors: Yu Ren, North Wales, PA (US); Shyam B. Karki, Lansdale, PA (US); Matthew M. Zhao, Edison, NJ (US); Mark T. Bidodeau, Lansdale, PA (US)

(51) Int. Cl.<sup>7</sup> ..... A61K 31/496; C07D 417/14

(52) U.S. Cl. ..... 514/253.1; 544/360

Correspondence Address:  
MERCK AND CO INC  
P O BOX 2000  
RAHWAY, NJ 070650907

(57) ABSTRACT


(21) Appl. No.: 10/607,114

The present invention relates to salt forms of 4-[2-(5-cyano-thiazol-2-ylamino)-pyridin-4-ylmethyl]-piperazine-1-carboxylic acid methylamide which inhibit, regulate and/or modulate tyrosine kinase signal transduction, compositions which contain these compounds, and methods of using them to treat tyrosine kinase-dependent diseases and conditions, such as angio-genesis, cancer, tumor growth, atherosclerosis, age related macular degeneration, diabetic retinopathy, retinal ischemia, macular edema, inflammatory diseases, and the like in mammals.

(22) Filed: Jun. 26, 2003

Related U.S. Application Data

(60) Provisional application No. 60/398,263, filed on Jul. 24, 2002.



FFB 2 1 2006

UNITED STATES PATENT AND TRADEMARK OFFICE

DOCKETED  
JAN 22 2004  
LORI SCHLESINGER

21068

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
[www.uspto.gov](http://www.uspto.gov)

APPL NO.	FILING OR 371 (c) DATE	ART UNIT	FIL FEE REC'D	ATTY.DOCKET NO	DRAWINGS	TOT CLMS	IND CLMS
10/607,114	06/26/2003	1624	1512	21068	11	53	5

## CONFIRMATION NO. 3654

## CORRECTED FILING RECEIPT



\*OC000000011729373\*

Date Mailed: 01/21/2004

Receipt is acknowledged of this regular Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Filing Receipt Corrections, facsimile number 703-746-9195. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

## Applicant(s)

Yu Ren, North Wales, PA;  
Shyam B. Karki, Lansdale, PA;  
Matthew M. Zhao, Edison, NJ;  
Mark T. Bilodeau, Lansdale, PA;

## Domestic Priority data as claimed by applicant

This appln claims benefit of 60/398,263 07/24/2002

## Foreign Applications

If Required, Foreign Filing License Granted: 09/30/2003

Projected Publication Date: 01/29/2004

Non-Publication Request: No

Early Publication Request: No

## Title

Salt forms with tyrosine kinase activity